Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reiter

Showing results (391-400 of 426) with videos related to

Pageof 43
Sort By:
Chemical Research in Toxicology|October 16, 2007
A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motifAmit S Kalgutkar, James Driscoll, Sabrina X Zhao, et al.
Klinische Padiatrie|May 24, 2013
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000M Schrappe, A Möricke, A Reiter, et al.
Leukemia|December 19, 2017
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cellsB Peter, S Bibi, G Eisenwort, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptorL A Reiter, K Koch, A D Piscopio, et al.
Frontiers in Neuroinformatics|February 13, 2016
Using Make for Reproducible and Parallel Neuroimaging Workflow and Quality-AssuranceMary K Askren, Trevor K McAllister-Day, Natalie Koh, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666Kenneth W Duncan, Nathalie Rioux, P Ann Boriack-Sjodin, et al.
Nature|April 10, 2020
Author Correction: Complete biosynthesis of cannabinoids and their unnatural analogues in yeastXiaozhou Luo, Michael A Reiter, Leo d'Espaux, et al.
Nature|March 1, 2019
Complete biosynthesis of cannabinoids and their unnatural analogues in yeastXiaozhou Luo, Michael A Reiter, Leo d'Espaux, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 1998
The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543H J Showell, M J Conklyn, R Alpert, et al.
Pageof 43

Showing results (391-400 of 426) with videos related to

Sort By:
Pageof 43
Chemical Research in Toxicology|October 16, 2007
A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motifAmit S Kalgutkar, James Driscoll, Sabrina X Zhao, et al.
Klinische Padiatrie|May 24, 2013
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000M Schrappe, A Möricke, A Reiter, et al.
Leukemia|December 19, 2017
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cellsB Peter, S Bibi, G Eisenwort, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptorL A Reiter, K Koch, A D Piscopio, et al.
Frontiers in Neuroinformatics|February 13, 2016
Using Make for Reproducible and Parallel Neuroimaging Workflow and Quality-AssuranceMary K Askren, Trevor K McAllister-Day, Natalie Koh, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666Kenneth W Duncan, Nathalie Rioux, P Ann Boriack-Sjodin, et al.
Nature|April 10, 2020
Author Correction: Complete biosynthesis of cannabinoids and their unnatural analogues in yeastXiaozhou Luo, Michael A Reiter, Leo d'Espaux, et al.
Nature|March 1, 2019
Complete biosynthesis of cannabinoids and their unnatural analogues in yeastXiaozhou Luo, Michael A Reiter, Leo d'Espaux, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 1998
The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543H J Showell, M J Conklyn, R Alpert, et al.
Pageof 43